The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited. A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption.
For patients with treatment-resistant schizophrenia, clozapine is a key antipsychotic. However, because clozapine is associated with hematological abnormalities, including neutropenia and leukopenia, patients must sometimes discontinue treatment. Sudden withdrawal of clozapine is linked with serious outcomes, however, including an increased risk of suicide.
The risk evaluation and mitigation strategy program for clozapine allows for patients to receive clozapine—even in the setting of moderate to severe neutropenia—if the benefit to psychiatric treatment outweighs the risk of recurrent neutropenia. However, literature that can guide appropriate treatment for such patients is limited.
A recently published case report suggests that using filgrastim to control leukopenia and neutropenia could allow patients to continue to receive clozapine without interruption. Published in The Mental Health Clinician, the report describes a 55-year-old male patient with chronic paranoid schizophrenia.
Learn more about filgrastim biosimilars.
The patient had achieved significant clinical improvement with clozapine treatment, and he attained functional independence without hospitalization. He was able to receive 20 years of clozapine therapy before he developed leukopenia, after which clozapine was withdrawn, precipitating a rapid worsening of his schizophrenia symptoms. Over the following 2 years, the patient tried, and had an inadequate response to, 7 other medications.
Because the patient’s symptoms were worsening, a retrial of clozapine was deemed necessary. However, 2 months after discharge from the hospital following psychiatric improvement with clozapine therapy, moderate leukopenia and mild neutropenia recurred, and his clozapine was once again held.
The patient was then treated with 5 daily doses of subcutaneous filgrastim (300 mcg/mL), and his white blood cells and absolute neutrophil count recovered within 4 days, allowing him to restart his clozapine. An interdisciplinary team determined that the patient could receive uninterrupted clozapine therapy with filgrastim as needed.
The patient had 1 period of leukopenia and neutropenia that necessitated interruption of clozapine, and his filgrastim was eventually replaced with a different colony-stimulating factor therapy (sargramostim) because of a formulary change, but over the past 3 years of receiving neutropenia treatment, his schizophrenia symptoms have been well controlled, and his clozapine use has been uninterrupted. The patient continues to have his white blood cells and absolute neutrophil count monitored weekly.
The authors of the case report conclude that filgrastim or sargramostim provide a potential alternative to clozapine discontinuation in the case of neutropenia for patients who have been clinically stable on their therapy.
Reference
Kars A, Lister J. Utilization of G-CSF and GM-CSF as an alternative to discontinuation in clozapine-induced neutropenia or leukopenia: a case report and discussion. Ment Health Clin. 2018;8(5):250-255. doi: 10.9740/mhc.2018.09.250.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.